— Know what they know.
Not Investment Advice
Also trades as: 0K1R.L (LSE) · $vol 0M

VRDN NASDAQ

Viridian Therapeutics, Inc.
1W: +7.4% 1M: +17.1% 3M: +21.2% YTD: -21.5% 1Y: +8.7% 3Y: +108.0% 5Y: +43.9%
$24.09
+0.75 (+3.21%)
 
Weekly Expected Move ±9.1%
$18 $20 $22 $24 $26
NASDAQ · Healthcare · Biotechnology · Tech Score Buy · Power 70 · $2.7B mcap · 106M float · 1.85% daily turnover · Short 57% of daily vol
Credit Risk of going bust: higher than 61% of companies Debt: 8.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.32 (down 99%), Viridian Therapeutics, Inc. would be worth roughly what it owes.
Total debt $242.9M against a stock market value of $2.73B.
Distance to default 4.13 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $121.8M (short-term plus half of long-term), stock volatility 74.2%; Altman Z'' 0.76. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Balance Sheet Trends

Total Assets
$899M +21.1% ▲
5Y CAGR: +46.9%
Total Liabilities
$177M +150.5% ▲
5Y CAGR: +73.7%
Shareholders Equity
$722M +7.5% ▲
5Y CAGR: +43.2%
Cash & Investments
$875M +21.9% ▲
5Y CAGR: +47.0%
Total Debt
$51M +140.3% ▲
5Y CAGR: +156.7%
Net Debt
-$162M -106.0% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$42M$156M$103M$100M$212M
Short-Term Investments$155M$269M$375M$618M$662M
Cash & ST Investments$197M$425M$477M$718M$875M
Net Receivables$451K$102K$102K$0$0
Inventory$0-$7M$0$0$0
Other Current Assets$0$7M$9M$21M$20M
Total Current Assets$200M$425M$486M$738M$894M
Property, Plant & Equip.$2M$3M$3M$3M$4M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$1M$8M$604K$501K$2M
Total Non-Current Assets$4M$11M$4M$4M$5M
Total Assets$204M$435M$490M$742M$899M
— Liabilities —
Accounts Payable$2M$14M$2M$2M$9M
Short-Term Debt$0$0$0$0$753K
Deferred Revenue$289K$288K$288K$288K$0
Other Current Liabilities$4M$5M$13M$11M$61M
Total Current Liabilities$14M$33M$27M$48M$71M
Long-Term Debt$0$5M$20M$21M$50M
Other Non-Current Liab.$1M$1M$989K$2M$57M
Total Non-Current Liabilities$2M$7M$22M$23M$107M
Total Liabilities$16M$40M$48M$71M$177M
— Equity —
Common Stock$239K$414K$540K$810K$1M
Retained Earnings-$358M-$488M-$726M-$996M-$1.3B
Accumulated OCI-$157K-$390K$338K-$10K$447K
Total Stockholders Equity$188M$395M$442M$672M$722M
Total Liabilities & Equity$204M$435M$490M$742M$899M
— Key Metrics —
Total Debt$520K$5M$21M$21M$51M
Net Debt-$42M-$150M-$82M-$78M-$162M
Total Investments$155M$269M$375M$618M$662M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms